Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes

被引：13

作者：

Yaribeygi, Habib ^{[1
]}

Atkin, Stephen L. ^{[2
]}

Sahebkar, Amirhossein ^{[3
,4
,5
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Chron Kidney Dis Res Ctr, Tehran, Iran

[2] Weill Cornell Med Qatar, Doha, Qatar

[3] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Razavi Khorasan, Iran

[4] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran

[5] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Razavi Khorasan, Iran

来源：

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS | 2019年 / 13卷 / 02期

关键词：

Sodium-glucose co-transporter inhibitors; Oxidative stress; Diabetes mellitus; Hypertension; INADEQUATE GLYCEMIC CONTROL; COTRANSPORTER; 2; INHIBITORS; DOUBLE-BLIND; OXIDATIVE STRESS; NITRIC-OXIDE; ADD-ON; GLOMERULAR HYPERFILTRATION; RENAL DYSFUNCTION; NERVOUS-SYSTEM; TYPE-2;

D O I：

10.1016/j.dsx.2019.03.031

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabetes mellitus prevalence is increasing worldwide leading to increased morbidity and mortality through diabetes related microvascular and macrovascular disease. The treatment of hypertension has been shown to be a major therapeutic intervention for the prevention of cardiovascular events and other diabetes related complications in diabetes. Sodium-glucose co-transporter inhibitors (SGLT2i) are newly introduced anti-diabetes drugs that lower blood glucose by the inhibition of glucose reuptake and the induction of glycosuria. However, there is increasing evidence showing their cardiovascular benefit beyond the improvement of glycemic control. Here we review the latest findings on the effect of SGLT2i on blood pressure in diabetes. (c) 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.

引用

页码：1679 / 1683

页数：5

共 50 条

[1] A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
Sokolov, Victor
Yakovleva, Tatiana
Stolbov, Leonid
Penland, Robert C.
Boulton, David
Parkinson, Joanna
Tang, Weifeng
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (06): : 831 - 841
[2] Effects of SGLT2 inhibitors on blood pressure and renal function
Nishiyama, Akira
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 130 (03) : S43 - S43
[3] EFFECTS OF SGLT2 INHIBITOR, TOFOGLIFLOZIN ON BLOOD PRESSURE AND BAPWV IN RESISTANT HYPERTENSION WITH TYPE 2 DIABETES
Yamagishi, T.
JOURNAL OF HYPERTENSION, 2019, 37 : E112 - E112
[4] Beyond Glycosuria: Exploring the intrarenal effects of SGLT2 inhibition in diabetes
Thomas, M. C.
Jandeleit-Dahm, K.
Bonnet, F.
DIABETES & METABOLISM, 2014, 40 : S17 - S22
[5] EFFECTS OF SGLT2 INHIBITORS ON CIRCADIAN RHYTHM OF BLOOD PRESSURE IN RATS
Rahman, Asadur
Takeshige, Yui
Fujisawa, Yoshihide
Hitomi, Hirofumi
Nakano, Daisuke
Nishiyama, Akira
JOURNAL OF HYPERTENSION, 2016, 34 : E391 - E391
[6] SGLT2 inhibition - a novel strategy for diabetes treatment
Chao, Edward C.
Henry, Robert R.
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (07) : 551 - 559
[7] SGLT2 inhibition — a novel strategy for diabetes treatment
Edward C. Chao
Robert R. Henry
Nature Reviews Drug Discovery, 2010, 9 : 551 - 559
[8] SGLT2 INHIBITION IN KIDNEY TRANSPLANT RECIPIENTS WITH DIABETES
Guthoff, M.
Mahling, M.
Nadalin, S.
Heyne, N.
TRANSPLANT INTERNATIONAL, 2017, 30 : 32 - 32
[9] Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes
Lauritsen, Katrine M.
Voigt, Jens Hohwu
Pedersen, Steen Bonlokke
Hansen, Troels K.
Moller, Niels
Jessen, Niels
Gormsen, Lars C.
Sondergaard, Esben
ENDOCRINE CONNECTIONS, 2022, 11 (04)
[10] Acute SGLT2 Inhibition and the Pressure Natriuresis Response in Rats with Type 1 Diabetes
Bailey, Matthew A.
Costello, Hannah M.
Stewart, Kevin
Binnie, David
Culshaw, Geoffrey C.
Webb, David J.
FASEB JOURNAL, 2019, 33

← 1 2 3 4 5 →